Antheia, a synthetic biology company working to develop plant-inspired medicine, has officially secured a fresh $73 million in Series B funding. The round, led by Viking Global Investors, will help further the company's goal to bring its first pharmaceutical compounds to market. for more on this, Christina Cmolke, CEO & Co-founder at Antheia joined Cheddar's Opening Bell.